We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Ruxolitinib therapy for myelofibrosis in Austria.
- Authors
Krauth, Maria-Theresa; Burgstaller, Sonja; Buxhofer-Ausch, Veronika; Gastl, Günther; Geissler, Klaus; Keil, Felix; Krippl, Peter; Melchardt, Thomas; Petzer, Andreas; Rumpold, Holger; Sliwa, Thamer; Wöhrer, Stefan; Wölfler, Albert; Gisslinger, Heinz
- Abstract
The oral Janus associated kinase (JAK1/2) inhibitor ruxolitinib has been available for treatment of patients with intermediate or high-risk myelofibrosis in Europe since 2012. Since its introduction, the expertise of prescribing doctors with respect to ruxolitinib function, efficacy and adverse effects has consistently been augmented, resulting in therapy modalities that are better tailored to individual patients as well as in increased safety of the treatment. The present consensus on ruxolitinib therapy management has been elaborated by Austrian experts in myeloproliferative neoplasms in line with international treatment guidelines. Our recommendations aim to contribute to an improved management of patients with myelofibrosis treated with ruxolitinib.
- Subjects
MYELOFIBROSIS; KINASE inhibitors; MYELOPROLIFERATIVE neoplasms; POLYCYTHEMIA; THERAPEUTICS; DISEASE risk factors
- Publication
Wiener Klinische Wochenschrift, 2018, Vol 130, Issue 17/18, p495
- ISSN
0043-5325
- Publication type
Article
- DOI
10.1007/s00508-018-1365-5